BridgeBio Pharma, Inc.
76.08USD
+1.3200 (+1.77%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 244 | 195 | 154 | 121 | 111 | 117 | 6 | 3 |
| Cost of Revenue | 15 | 10 | 8 | 7 | 4 | 3 | 2 | 1 |
| Gross Profit | 229 | 185 | 146 | 114 | 107 | 114 | 4 | 2 |
| Operating Income | -107 | -106 | -140 | -145 | -134 | -104 | -226 | -192 |
| Net Income | -156 | -167 | -195 | -185 | -184 | -170 | -267 | -164 |
| EPS (Diluted) | $-0.78 | $-0.84 | $-0.99 | $-0.95 | $-0.95 | $-0.88 | $-1.42 | $-0.86 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)